View this email in your browser Feature: AltMed Capital Corp. Who: A leading psychedelic medicine clinic operator, IP aggregator, and solutions provider, AltMed Capital is mandated with accelerating advancements in the psychedelic medicine arena. View Corporate Presentation Traction/Strategy: Fully operational clinic in Mississauga, Ontario with 16 months of operating history The only Health Canada Approved Clinic for Randomized Controlled Trial (RCT) for Psilocybin Over 1,500 ketamine treatments administered and ~$1,000,000 in revenue in first full year of operations



AltMed will leverage Dr. McIntyre's expertise, alongside its existing SOP's, data driven research sets and practitioner education modules to roll-out five unique Ketamine Clinics across Florida, California and the US Eastern Seaboard. AltMed's additional Ketamine Clinics are expected to be operational by Fall 2020.



AltMed will leverage its preferred commercial relationship with InterVivo to expedite Phase 1 testing and novel drug development of its psychedelic molecules and proprietary delivery systems.



AltMed will offer a sub-specialty therapeutic clinic, as a complementary, follow-on service offering for individuals and families who are suffering from effects of addiction, depression, post-traumatic stress disorder, and anxiety disorders. Team:

Dr. Roger McIntyre, President and CEO Professor of Psychiatry and Pharmacology, University of Toronto

Head of Mood Disorders Psychopharmacology, University Health Network Pat McCutcheon, Director Founder, CEO of MediPharm Labs (TSX: LABS)

15 years of experience in the pharmaceutical industry in top sales roles Summary: AltMed is a true first mover in Psychedelic medicine, being the first and only clinic in Canada to currently conduct Health Canada approved randomized controlled trials for psilocybin. They are a leader in ketamine treatments and have best in class medical processes that have delivered incredible outcomes for their many current patients. Moving ahead, they will look to be as innovative and disruptive in their search to generate new delivery systems and scientific IP around Psychedelic medicines.